Wellesley, MA, March 19, 2018
– Ampersand Capital Partners is pleased to announce the closing of the firm’s latest fund, Ampersand 2018 (“AMP-18”) Limited Partnership, with $450 million in limited partner commitments. This fund, which is Ampersand’s ninth fund since 1992, was significantly oversubscribed and held a single close three months after launch.
Ampersand Managing General Partner, Herb Hooper, commented, “We greatly appreciate the strong support from both existing and new investors, and their confidence in Ampersand’s differentiated healthcare investment strategy.” Ampersand secured commitments from a diversified group of institutional investors including endowments, foundations, pension plans, insurance companies, multi-manager funds and family offices.
With this new fund, Ampersand plans to continue the firm’s strategy of making growth-oriented investments within targeted sectors of the healthcare industry. Ampersand focuses on both majority and minority investments in companies with $10 to $100 million in revenues and positive EBITDA.
Goodwin Procter LLP provided legal services to Ampersand for this fundraise.
ABOUT AMPERSAND CAPITAL PARTNERS
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com
This press release is not an offer or solicitation of an offer, or an invitation or inducement, to invest in any Ampersand fund. No person may invest in any Ampersand fund except in accordance with and subject to the terms of the applicable fund documentation and applicable law.